1. Home
  2. PLSE vs MESO Comparison

PLSE vs MESO Comparison

Compare PLSE & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$28.58

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$16.61

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
MESO
Founded
2014
2004
Country
United States
Australia
Employees
N/A
81
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
PLSE
MESO
Price
$28.58
$16.61
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$22.00
N/A
AVG Volume (30 Days)
329.0K
220.4K
Earning Date
05-07-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$840.00
$629.74
Revenue Next Year
$287.54
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.56
$12.66
52 Week High
$31.00
$21.50

Technical Indicators

Market Signals
Indicator
PLSE
MESO
Relative Strength Index (RSI) 57.53 58.87
Support Level $23.94 $13.82
Resistance Level $31.00 $17.33
Average True Range (ATR) 1.58 0.66
MACD -0.05 0.30
Stochastic Oscillator 70.14 53.53

Price Performance

Historical Comparison
PLSE
MESO

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: